PDCD1 and cancer: Based on the physiological properties of CTLA-4 and PD-1 revealed by the extensive studies outlined above, it is anticipated that blockade of these ICs in humans for cancer therapy will inevitably lead to global immune activation leading to autoimmune manifestations of various organ systems (Figure 1).